WallStSmart

AngioDynamics Inc (ANGO)vsMedline Inc. Class A Common Stock (MDLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 9152% more annual revenue ($28.43B vs $307.31M). MDLN leads profitability with a 4.1% profit margin vs -9.0%. MDLN earns a higher WallStSmart Score of 52/100 (C-).

ANGO

Hold

43

out of 100

Grade: D

Growth: 4.0Profit: 2.0Value: 6.7Quality: 5.0

MDLN

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 5.0Value: 8.3Quality: 7.8
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ANGO.

MDLNUndervalued (+32.7%)

Margin of Safety

+32.7%

Fair Value

$66.92

Current Price

$42.67

$24.25 discount

UndervaluedFair: $66.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ANGO1 strengths · Avg: 8.0/10
Price/BookValuation
2.5x8/10

Reasonable price relative to book value

MDLN0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ANGO4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$429.07M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-15.3%2/10

ROE of -15.3% — below average capital efficiency

Profit MarginProfitability
-9.0%1/10

Currently unprofitable

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
29.9x4/10

Moderate valuation

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ANGO

The strongest argument for ANGO centers on Price/Book. PEG of 1.41 suggests the stock is reasonably priced for its growth.

Bull Case : MDLN

Revenue growth of 14.8% demonstrates continued momentum.

Bear Case : ANGO

The primary concerns for ANGO are EPS Growth, Market Cap, Return on Equity.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

ANGO profiles as a turnaround stock while MDLN is a value play — different risk/reward profiles.

MDLN is growing revenue faster at 14.8% — sustainability is the question.

ANGO generates stronger free cash flow (4M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (52/100 vs 43/100) and 14.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AngioDynamics Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

AngioDynamics, Inc. designs, manufactures and sells various medical, surgical and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company is headquartered in Latham, New York.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Want to dig deeper into these stocks?